Travere Therapeutics (NASDAQ:TVTX) Issues Earnings Results, Misses Expectations By $0.15 EPS

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.73) earnings per share for the quarter, missing analysts' consensus estimates of ($0.58) by ($0.15), Zacks reports. Travere Therapeutics had a negative net margin of 172.75% and a negative return on equity of 537.74%.

Travere Therapeutics Stock Performance

TVTX traded up $0.25 during midday trading on Thursday, reaching $23.58. The company's stock had a trading volume of 1,324,115 shares, compared to its average volume of 1,592,714. Travere Therapeutics has a twelve month low of $5.12 and a twelve month high of $25.29. The stock has a market cap of $1.84 billion, a P/E ratio of -5.18 and a beta of 0.72. The company has a fifty day simple moving average of $19.47 and a 200 day simple moving average of $16.43. The company has a current ratio of 1.71, a quick ratio of 1.68 and a debt-to-equity ratio of 24.96.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on TVTX. Barclays lifted their price target on Travere Therapeutics from $18.00 to $20.00 and gave the stock an "overweight" rating in a research report on Friday, November 1st. Scotiabank raised their price objective on Travere Therapeutics from $27.00 to $32.00 and gave the company a "sector outperform" rating in a report on Wednesday, February 12th. Canaccord Genuity Group lifted their price target on Travere Therapeutics from $22.00 to $45.00 and gave the stock a "buy" rating in a research note on Wednesday, February 12th. Cantor Fitzgerald started coverage on shares of Travere Therapeutics in a report on Friday, January 10th. They issued an "overweight" rating on the stock. Finally, Piper Sandler lifted their target price on Travere Therapeutics from $12.00 to $22.00 and gave the company a "neutral" rating in a research report on Thursday, November 14th. One analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $27.77.

Insider Buying and Selling

In related news, SVP William E. Rote sold 5,200 shares of Travere Therapeutics stock in a transaction dated Wednesday, February 12th. The stock was sold at an average price of $23.53, for a total value of $122,356.00. Following the completion of the transaction, the senior vice president now directly owns 98,519 shares of the company's stock, valued at $2,318,152.07. The trade was a 5.01 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CAO Sandra Calvin sold 15,000 shares of Travere Therapeutics stock in a transaction dated Thursday, December 26th. The stock was sold at an average price of $17.22, for a total value of $258,300.00. Following the completion of the sale, the chief accounting officer now owns 54,927 shares of the company's stock, valued at approximately $945,842.94. The trade was a 21.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 218,425 shares of company stock valued at $4,674,259. 3.75% of the stock is owned by company insiders.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.